Metformin Targets Foxo1 to Control Glucose Homeostasis

• Main Authors: Xiaoqin Guo, Xiaopeng Li, Wanbao Yang, Wang Liao, James Zheng Shen, Weiqi Ai, Quan Pan, Yuxiang Sun, Kebin Zhang, Rui Zhang, Yuyang Qiu, Qian Dai, Hongting Zheng, Shaodong Guo
• Format: Article
• Language: English
• Published: MDPI AG 2021-06-01
• Series: Biomolecules
• Subjects: metformin; salicylate; Foxo1-S273 phosphorylation; type 2 diabetes; glucose homeostasis
• Online Access: https://www.mdpi.com/2218-273X/11/6/873

Metformin is the first-line pharmacotherapy for type 2 diabetes mellitus (T2D). Metformin exerts its glucose-lowering effect primarily through decreasing hepatic glucose production (HGP). However, the precise molecular mechanisms of metformin remain unclear due to supra-pharmacological concentration of metformin used in the study. Here, we investigated the role of Foxo1 in metformin action in control of glucose homeostasis and its mechanism via the transcription factor Foxo1 in mice, as well as the clinical relevance with co-treatment of aspirin. We showed that metformin inhibits HGP and blood glucose in a Foxo1-dependent manner. Furthermore, we identified that metformin suppresses glucagon-induced HGP through inhibiting the PKA→Foxo1 signaling pathway. In both cells and mice, Foxo1-S273D or A mutation abolished the suppressive effect of metformin on glucagon or fasting-induced HGP. We further showed that metformin attenuates PKA activity, decreases Foxo1-S273 phosphorylation, and improves glucose homeostasis in diet-induced obese mice. We also provided evidence that salicylate suppresses HGP and blood glucose through the PKA→Foxo1 signaling pathway, but it has no further additive improvement with metformin in control of glucose homeostasis. Our study demonstrates that metformin inhibits HGP through PKA-regulated transcription factor Foxo1 and its S273 phosphorylation.